Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53

Experimental Cell Research

Volumn 317, Issue 7, 2011, Pages 1060-1070

  Sung, Ki Sa ^a   Lee, Yun Ah ^a   Kim, Eui Tae ^b   Lee, Seung Rock ^c   Ahn, Jin Hyun ^b   Choi, Cheol Yong ^a  

^a Sungkyunkwan University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Chonnam National University Medical School   (South Korea)

Author keywords

HIPK2; P53 phosphorylation; PML; SUMO interaction motif

Indexed keywords

ANTINUCLEAR ANTIBODY; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; SERINE; SUMO PROTEIN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; WILD TYPE;

EID: 79952455179     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.12.016     Document Type: Article

References (50)

1. de The H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:675-684.
2. Goddard A.D., Borrow J., Freemont P.S., Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991, 254:1371-1374.
3. Kakizuka A., Miller W.H., Umesono K., Warrell R.P., Frankel S.R., Murty V.V., Dmitrovsky E., Evans R.M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991, 66:663-674.
4. Kastner P., Perez A., Lutz Y., Rochette-Egly C., Gaub M.P., Durand B., Lanotte M., Berger R., Chambon P. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J. 1992, 11:629-642.
5. Weidtkamp-Peters S., Lenser T., Negorev D., Gerstner N., Hofmann T.G., Schwanitz G., Hoischen C., Maul G., Dittrich P., Hemmerich P. Dynamics of component exchange at PML nuclear bodies. J. Cell Sci. 2008, 121:2731-2743.
6. Brand P., Lenser T., Hemmerich P. Assembly dynamics of PML nuclear bodies in living cells. PMC Biophys. 2010, 3:3.
7. Shen T.H., Lin H.K., Scaglioni P.P., Yung T.M., Pandolfi P.P. The mechanisms of PML-nuclear body formation. Mol. Cell 2006, 24:331-339.
8. Cho G., Lim Y., Golden J.A. SUMO interaction motifs in Sizn1 are required for promyelocytic leukemia protein nuclear body localization and for transcriptional activation. J. Biol. Chem. 2009, 284:19592-19600.
9. Takahashi H., Hatakeyama S., Saitoh H., Nakayama K.I. Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein. J. Biol. Chem. 2005, 280:5611-5621.
10. Lin D.Y., Huang Y.S., Jeng J.C., Kuo H.Y., Chang C.C., Chao T.T., Ho C.C., Chen Y.C., Lin T.P., Fang H.I., Hung C.C., Suen C.S., Hwang M.J., Chang K.S., Maul G.G., Shih H.M. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 2006, 24:341-354.
11. Kim E.T., Kim Y.E., Huh Y.H., Ahn J.H. Role of noncovalent SUMO binding by the human cytomegalovirus IE2 transactivator in lytic growth. J. Virol. 2010, 84:8111-8123.
12. Mimura Y., Takahashi K., Kawata K., Akazawa T., Inoue N. Two-step colocalization of MORC3 with PML nuclear bodies. J. Cell Sci. 2010, 123:2014-2024.
13. Jensen K., Shiels C., Freemont P.S. PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001, 20:7223-7233.
14. Condemine W., Takahashi Y., Zhu J., Puvion-Dutilleul F., Guegan S., Janin A., de The H. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 2006, 66:6192-6198.
15. Nguyen L.A., Pandolfi P.P., Aikawa Y., Tagata Y., Ohki M., Kitabayashi I. Physical and functional link of the leukemia-associated factors AML1 and PML. Blood 2005, 105:292-300.
16. Bischof O., Kirsh O., Pearson M., Itahana K., Pelicci P.G., Dejean A. Deconstructing PML-induced premature senescence. EMBO J. 2002, 21:3358-3369.
17. Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2000, 2:730-736.
18. Moilanen A.M., Karvonen U., Poukka H., Janne O.A., Palvimo J.J. Activation of androgen receptor function by a novel nuclear protein kinase. Mol. Biol. Cell 1998, 9:2527-2543.
19. Trost M., Kochs G., Haller O. Characterization of a novel serine/threonine kinase associated with nuclear bodies. J. Biol. Chem. 2000, 275:7373-7377.
20. Kim Y.H., Choi C.Y., Lee S.J., Conti M.A., Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J. Biol. Chem. 1998, 273:25875-25879.
21. Puca R., Nardinocchi L., Givol D., D'Orazi G. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 2010, 29:4378-4387.
22. Sombroek D., Hofmann T.G. How cells switch HIPK2 on and off. Cell Death Differ. 2009, 16:187-194.
23. Bitomsky N., Hofmann T.G. Apoptosis and autophagy: regulation of apoptosis by DNA damage signalling - roles of p53, p73 and HIPK2. FEBS J. 2009, 276:6074-6083.
24. Wei G., Ku S., Ma G.K., Saito S., Tang A.A., Zhang J., Mao J.H., Appella E., Balmain A., Huang E.J. HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc. Natl Acad. Sci. USA 2007, 104:13040-13045.
25. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Appella E., Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 2002, 4:11-19.
26. Hofmann T.G., Moller A., Sirma H., Zentgraf H., Taya Y., Droge W., Will H., Schmitz M.L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 2002, 4:1-10.
27. Pistritto G., Puca R., Nardinocchi L., Sacchi A., D'Orazi G. HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ. 2007, 14:1837-1839.
28. Puca R., Nardinocchi L., Sacchi A., Rechavi G., Givol D., D'Orazi G. HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol. Cancer 2009, 8:85.
29. Kim Y.H., Choi C.Y., Kim Y. Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1. Proc. Natl Acad. Sci. USA 1999, 96:12350-12355.
30. Sung K.S., Go Y.Y., Ahn J.H., Kim Y.H., Kim Y., Choi C.Y. Differential interactions of the homeodomain-interacting protein kinase 2 (HIPK2) by phosphorylation-dependent sumoylation. FEBS Lett. 2005, 579:3001-3008.
31. Hofmann T.G., Jaffray E., Stollberg N., Hay R.T., Will H. Regulation of homeodomain-interacting protein kinase 2 (HIPK2) effector function through dynamic small ubiquitin-related modifier-1 (SUMO-1) modification. J. Biol. Chem. 2005, 280:29224-29232.
32. Gresko E., Moller A., Roscic A., Schmitz M.L. Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability. Biochem. Biophys. Res. Commun. 2005, 329:1293-1299.
33. Engelhardt O.G., Boutell C., Orr A., Ullrich E., Haller O., Everett R.D. The homeodomain-interacting kinase PKM (HIPK-2) modifies ND10 through both its kinase domain and a SUMO-1 interaction motif and alters the posttranslational modification of PML. Exp. Cell Res. 2003, 283:36-50.
34. Moller A., Sirma H., Hofmann T.G., Rueffer S., Klimczak E., Droge W., Will H., Schmitz M.L. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res. 2003, 63:4310-4314.
35. Choi D.W., Seo Y.M., Kim E.A., Sung K.S., Ahn J.W., Park S.J., Lee S.R., Choi C.Y. Ubiquitination and degradation of homeodomain-interacting protein kinase 2 by WD40 repeat/SOCS box protein WSB-1. J. Biol. Chem. 2008, 283:4682-4689.
36. Kim E.A., Noh Y.T., Ryu M.J., Kim H.T., Lee S.E., Kim C.H., Lee C., Kim Y.H., Choi C.Y. Phosphorylation and transactivation of Pax6 by homeodomain-interacting protein kinase 2. J. Biol. Chem. 2006, 281:7489-7497.
37. Song J., Durrin L.K., Wilkinson T.A., Krontiris T.G., Chen Y. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc. Natl Acad. Sci. USA 2004, 101:14373-14378.
38. Minty A., Dumont X., Kaghad M., Caput D. Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J. Biol. Chem. 2000, 275:36316-36323.
39. Hecker C.M., Rabiller M., Haglund K., Bayer P., Dikic I. Specification of SUMO1- and SUMO2-interacting motifs. J. Biol. Chem. 2006, 281:16117-16127.
40. Zhu J., Zhu S., Guzzo C.M., Ellis N.A., Sung K.S., Choi C.Y., Matunis M.J. Small ubiquitin-related modifier (SUMO) binding determines substrate recognition and paralog-selective SUMO modification. J. Biol. Chem. 2008, 283:29405-29415.
41. Meulmeester E., Kunze M., Hsiao H.H., Urlaub H., Melchior F. Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25. Mol. Cell 2008, 30:610-619.
42. Merrill J.C., Melhuish T.A., Kagey M.H., Yang S.H., Sharrocks A.D., Wotton D. A role for non-covalent SUMO interaction motifs in Pc2/CBX4 E3 activity. PLoS ONE 2010, 5:e8794.
43. Yang S.H., Sharrocks A.D. The SUMO E3 ligase activity of Pc2 is coordinated through a SUMO interaction motif. Mol. Cell. Biol. 2010, 30:2193-2205.
44. Knipscheer P., Flotho A., Klug H., Olsen J.V., van Dijk W.J., Fish A., Johnson E.S., Mann M., Sixma T.K., Pichler A. Ubc9 sumoylation regulates SUMO target discrimination. Mol. Cell 2008, 31:371-382.
45. Kim E.T., Kim K.K., Matunis M.J., Ahn J.H. Enhanced SUMOylation of proteins containing a SUMO-interacting motif by SUMO-Ubc9 fusion. Biochem. Biophys. Res. Commun. 2009, 388:41-45.
46. Hofmann T.G., Stollberg N., Schmitz M.L., Will H. HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res. 2003, 63:8271-8277.
47. Gresko E., Ritterhoff S., Sevilla-Perez J., Roscic A., Frobius K., Kotevic I., Vichalkovski A., Hess D., Hemmings B.A., Schmitz M.L. PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage. Oncogene 2009, 28:698-708.
48. Moller A., Sirma H., Hofmann T.G., Staege H., Gresko E., Ludi K.S., Klimczak E., Droge W., Will H., Schmitz M.L. Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression. Oncogene 2003, 22:8731-8737.
49. Li Q., Wang X., Wu X., Rui Y., Liu W., Wang J., Liou Y.C., Ye Z., Lin S.C. Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res. 2007, 67:66-74.
50. Negorev D., Maul G.G. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 2001, 20:7234-7242.